<DOC>
	<DOCNO>NCT01302990</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , active- placebo-controlled , multicenter , dose-ranging study evaluate safety , tolerability Immunogenicity single non-adjuvanted dose H1 VLP Influenza vaccine healthy adult 18-49 year age .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Plant-Made H1 VLP Influenza Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Male female adult , 18 49 year age ; Healthy judge Principal Investigator ( PI ) designee determine medical history , physical examination , vital sign , screen laboratory medical history conduct 30 day prior study vaccine administration ; BMI ≥ 18 ≤ 32 ; Comprehension study requirement , express availability require study period ability attend schedule visit ; Accessible telephone consistent basis ; In opinion Investigator , competence willingness provide write , informed consent participation reading inform consent form . The subject must adequate opportunity discus study Investigator qualify designee ; Showing HI titer &lt; 1/40 swineorigin A/California/07/2009 H1N1like X179A strain serum screen period ; If female childbearing potential , negative serum pregnancy test result prior vaccination . Female post menopausal ( spot ) least 2 year require pregnancy test ; If female capable childbearing , consistently use effective birth control 28 day prior vaccination . An example highly effective birth control oral contraceptive , hormone implant , abstinence ( confirmed Investigator ) , male condom plus spermicide . All female childbearing potential , must provide serum sample pregnancy screen . Female child bear potential ( except subject sex relationship ) must agree continue employ adequate birth control measure least 60 day post vaccination must plan become pregnant least 60 day post vaccination ; Presence significant acute chronic , uncontrolled medical neuropsychiatric illness . `` Uncontrolled '' define : 1 . Requiring new medical surgical treatment within one month prior study vaccine administration ; 2 . Requiring change medication dosage one month prior study vaccine administration due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) , 3 . Hospitalization event fulfil definition serious adverse event within one month prior study vaccine administration ; Any medical neuropsychiatric condition history excessive alcohol use drug abuse , Investigator 's opinion , would render subject incompetent provide inform consent unable provide valid safety observation report ; Any confirm suspected immunosuppressive condition immunodeficiency include history human immunodeficiency virus ( HIV ) infection , Hepatitis B C , presence lymphoproliferative disease ; Presence febrile illness , oral temperature &gt; 38.0˚C ( 100.4˚F ) within 24 hour prior randomization . Such subject may reevaluate randomization resolution illness ; History autoimmune disease ; Administration vaccine ( include influenza vaccine ) within 30 day period prior study enrollment , plan administration within period first vaccination blood sample Day 21 within 30 day prior blood sample Day 201 . Immunization emergency basis tetanus diphtheria toxoid adsorb adult use ( Td ) allow provide vaccine administer within two week prior study vaccine administration . Receipt emergency immunization ( e.g . rabies ) result casebycase review medical monitor continue participation ; Use investigational nonmarketed product within 30 day prior study enrollment plan use study period . Subjects may participate investigational market drug study participate study ; Treatment systemic glucocorticoid dose exceed 10 mg prednisone per day , equivalent 7 consecutive day 10 day total , within one month first study vaccine administration , cytotoxic immunosuppressant drug within three month vaccination . Use immune globulin product Use high dose inhale steroid oral parenteral high dose steroid medication . Nasal steroids allow . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin [ eg &lt; /= 325 mg/day ( 1 regular adult aspirin ) &lt; /= 81 mg/day ( 1 baby aspirin ) ] , without clinically apparent bleeding tendency eligible ; History allergy constituent H1 VLP ( H1N1 ) study vaccine , phosphate buffer ; History allergy eggbased vaccine allergy hypersensitivity egg protein . History severe allergic reaction anaphylaxis severe asthma ; History tobacco allergy ; History antihistaminics use continuously 4 week time past year , prior randomization ; Have rash , dermatological condition tattoo may interfere injection site reaction rating ; Have receive blood transfusion within 90 day prior vaccination ; If female , either know pregnancy urine betahuman chorionic gonadotropin ( ßhCG ) test result consistent pregnancy screen period prior study vaccine administration Day 0 ; Female subject lactate ; Any vital sign abnormality : systolic blood pressure , diastolic blood pressure , rest pulse rate well control accord Investigator 's opinion ; Cancer treatment cancer within 3 year study vaccine administration . Persons history cancer diseasefree without treatment 3 year eligible . Persons treat uncomplicated basal cell carcinoma skin eligible . Subject history Gillian Barre Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Respiratory disease</keyword>
	<keyword>Prevention</keyword>
</DOC>